Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

First International Summit on Interventional Pharmacoeconomics

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Peter Clark, MA, MD, FRCP: A Payer Perspective

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Deborah Collyar: What's In It for Patients?

Nivolumab Injected Directly Into Spinal Fluid May Be Safe and Effective for Some Patients With Melanoma Who Have Leptomeningeal Disease

Hypercalcemia in Patients With Cholangiocarcinoma

Effect of Insurance Status on Racial and Ethnic Inequities in the Diagnosis of Advanced-Stage Cervical Cancer

Extended Performance of an Image-Based Short-Term Risk Model for Predicting Breast Cancer

Researchers Uncover How Incurable Skin Cancer May Resist Treatment at the End of Life